Back

Biomarkers in action: The role of Procalcitonin, NT-proBNP, and Troponin T in predicting septic cardiomyopathy

17 May 2025 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Markers in and of dilated cardiomyopathy Dilated Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mr Diogo Ferreira

Santa Maria Hospital - CHULN, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Influence of non-sex specific risk factors on the development of a dilated cardiomyopathy in men and women with a titin truncating variant
Ms I. Faassen (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Phenotypic manifestation based on genetics and prevalence of secondary mutations in a sample of patients diagnosed with arrhythmogenic cardiomyopathy
Doctor A. Diaz Exposito (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
Genetic determinants of disease severity in idiopathic dilated cardiomyopathy
Associate Professor J. Lee (Cheongju, KR)
Abstract Slides Video
Presentation thumbnail
Relationship between TTN gene mutation and changes in whole-heart myocardial mechanics in patients with non-ischemic dilated cardiomyopathy: feature-tracking CMR study
Ms G. Jakuskaite (Kaunas, LT)
Abstract Slides Video
Presentation thumbnail
Is left ventricular ejection fraction an effective predictor of ventricular arrhythmias in patients with dilated cardiomyopathy?
Doctor M. Rodrigues Simoes (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Markers in and of dilated cardiomyopathy

The Event

Event poster

Heart Failure 2025

17 May 2025 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Sepsis-induced cardiac dysfunction: echocardiographic patterns and outcome implications
thumbnail
Congress Presentation
Exploring the significance of procalcitonin in cardiogenic shock for the prediction of infection and mortality outcomes
thumbnail
Congress Presentation
Unveiling the population dynamics of sepsis cardiomyopathy: a comprehensive evaluation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources